louisakewell, Author at European Medical Journal - Page 103 of 153

Pregnancy in Chronic Arthritis: Only a Matter of Planning

Chronic arthritis often affects women of childbearing age. The old concept that having chronic arthritis constitutes a major obstacle to women when…

Obesity and Osteoarthritis: More Than Just Mechanics

Osteoarthritis (OA) is the most common form of arthritis worldwide. It results in chronic pain, functional limitations, and significant social and…

Diffuse Large B Cell Lymphoma of the Foot in a Patient with Rheumatoid Arthritis

Patients with rheumatoid arthritis (RA) have an increased risk of developing malignant lymphomas, especially non-Hodgkin’s lymphoma (NHL).

Deciphering Ectopic Calcification: Contribution of the Rare, Inherited Disorder Pseudoxanthoma Elasticum

Soft connective tissue calcification is still an intriguing problem due to the high number of genes, proteins, and enzymes involved in the process.

Axial Spondyloarthritis: An Evolving Concept

Axial spondyloarthritis (AxSpA) is the prototype of a family of inter-related yet heterogeneous diseases sharing common clinical and genetic…

Interview with Prof. Iain McInnes at EULAR 2015

Interview with Prof. Iain McInnes at the European League Against Rheumatism (EULAR) 2015 discussing his research on spondyloarthritis.

EMJ

PERSIST-2: Phase 3 trial of pacritinib versus best available therapy for myelofibrosis

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX, discusses the ongoing PERSIST-2…

EMJ

Emerging immunotherapies for kidney cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…

EMJ

Phase 3 COMBI-d trial of dabrafenib plus trametinib in metastatic

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK…

EMJ

ARAMIS: Phase 3 trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France…